Prostate cancer is a significant health concern that affects men, particularly as they age. Understanding the intricacies of this disease is essential for early detection, personalized treatment, and improved outcomes.
Prostate cancer is a type of cancer that develops in the prostate gland, a small walnut-shaped gland in men that produces seminal fluid. It is one of the most common types of cancer in men, with an estimated 288,300 new cases and 34,700 deaths in the United States in 2023. In this article, we will discuss the statistics, recovery chances, stages of the cancer, common treatments, and a therapy that is becoming more and more known worldwide, Dendritic Cell Therapy for prostate cancer.
Prostate cancer is the second leading cause of cancer death in men in the United States, after lung cancer. It is most commonly diagnosed in men over the age of 65, with the average age at diagnosis being 66. African American men are at a higher risk of developing prostate cancer and are more likely to die from the disease than other racial groups. Other risk factors for prostate cancer include a family history of the disease, obesity, and a diet high in fat.
The prognosis for prostate cancer varies depending on several factors, including the stage of the cancer, the age and overall health of the patient, and the treatment chosen. The five-year survival rate for prostate cancer is nearly 100% for men with localized or regional disease. However, for men with distant metastases, the five-year survival rate drops to around 30%.
Prostate cancer is typically staged based on the TNM system, which stands for Tumour, Node, and Metastasis. The T category describes the size and extent of the primary tumour, the N category describes whether the cancer has spread to nearby lymph nodes, and the M category describes whether the cancer has spread to other parts of the body.
T1a: The cancer is found incidentally during a biopsy or surgery for another reason, and involves less than 5% of one lobe of the prostate.
T1b: The cancer is found incidentally during a biopsy or surgery for another reason, and involves more than 5% of one lobe of the prostate.
T1c: The cancer is detected by a prostate-specific antigen (PSA) blood test, but not by digital rectal examination (DRE) or imaging tests.
T2a: The cancer is only in one half of one lobe of the prostate.
T2b: The cancer is in more than one half of one lobe of the prostate, but not in both lobes.
T2c: The cancer is in both lobes of the prostate.
T3a: The cancer has spread beyond the prostate capsule to involve nearby tissues, such as the seminal vesicles.
T3b: The cancer has spread to the neck of the bladder or the external sphincter muscle.
T4: The cancer has spread to nearby organs, such as the rectum, bladder, or pelvic wall.
N1: The cancer has spread to nearby lymph nodes.
M1: The cancer has spread to distant organs or tissues, such as the bones or liver.
Within each stage, there may be subclassifications based on the specific size and extent of the tumour, as well as the number and location of lymph nodes involved. The TNM system is used by doctors to plan treatment and to predict a patient’s prognosis.
The treatment for prostate cancer depends on the stage of the cancer, the patient’s age and overall health, and other factors. Common treatments for prostate cancer include:
Active surveillance: Monitoring the cancer closely with regular checkups, but not treating it right away.
Surgery: Removal of the prostate gland, known as a prostatectomy.
Radiation therapy: Use of high-energy radiation to kill cancer cells.
Hormone therapy: Use of medications to block the hormones that fuel prostate cancer growth.
Chemotherapy: Use of drugs to kill cancer cells throughout the body.
Immunotherapy: Use of drugs that help the immune system fight cancer cells.
The Dendritic cell therapy by Immucura is a type of immunotherapy that has shown promise in the treatment of prostate cancer.
How does it work?
Immucura works with the patient’s own immune cells to help them fight prostate cancer. By collecting and modifying dendritic cells in the laboratory, we can boost their ability to recognize and target cancer cells. Once we inject these modified cells back into the patient, they can stimulate a strong immune response against the cancer. It is gratifying to see that this approach has helped to slow the growth of prostate cancer and improve the quality of life of our patients.
Thanks to the testimonials of Immucura’s patients about their experiences, other cancer patients can consider the option of this therapy, which is also natural and can be combined with any other cancer therapy at the same time. Here is one from our patient Dennis: “Initially, I was told by a consultant that I got lung cancer and that I was too weak to be treated with chemotherapy, and he gave me nine months to live. I was in shock. I went on the computer to see what else there was, and I came across Immucura. I was impressed with what I read, so I contacted Immucura. Eventually, I had Immunotherapy and also Nanothermia.
I did not have any side effects at all, and now I feel much better now, I am alert physically. The team is fantastic, everybody is there to help with everything required.
I would suggest it to anybody, try immunotherapy, it worked for me. I am still alive after three years.”
In this link, you can find more stories of our patients: Success stories